Terumo Boston Consulting Group Matrix
See the Bigger Picture
Terumo’s BCG Matrix snapshot highlights how its core product lines balance market share and growth potential, revealing which offerings are powering profits and which need strategic reevaluation. This concise preview shows movement across Stars, Cash Cows, Question Marks, and Dogs—essential context for portfolio and capital-allocation decisions. Purchase the full BCG Matrix for a complete quadrant-by-quadrant breakdown, data-driven recommendations, and ready-to-use Word and Excel deliverables to guide immediate strategic action.
Stars
TAVI and Structural Heart Devices
As of late 2025 Terumo’s TAVI and structural-heart devices are Stars: the segment grew ~18% CAGR 2020–2024 and accounted for roughly ¥70–80bn (≈$500–580m) revenue in FY2024, driven by aging populations and a shift to minimally invasive procedures.
Terumo is plowing double-digit percentage of revenue from this unit into R&D and trials to defend share versus Edwards, Medtronic and Abbott, keeping the business cash-hungry but positioned for long-term market leadership.
Neurovascular Intervention Systems
Terumo’s Neurovascular Intervention Systems, focused on stroke thrombectomy and aneurysm repair, is a Star: global stroke care expansion drove ~12% CAGR 2019–2024 in neuro devices, and Terumo reported neurovascular revenue of ¥42.3bn (≈$280m) in FY2024, holding top-three share in stents and coils used in mechanical thrombectomy.
Digital Health and Remote Monitoring
Integrating digital solutions into diabetes care and hospital workflows became a primary growth engine for Terumo by end-2025, driving a 14% CAGR in connected-device revenue to ¥112 billion (≈$800M) in FY2025.
Software-integrated devices captured 9% global hospital monitor share in 2025 as facilities shifted to data-driven care, boosting recurring software/licenses to 22% of product sales.
These offerings need heavy upfront R&D and cybersecurity spend—R&D up 28% to ¥36 billion in 2025—but they underpin Terumo’s future competitive edge and higher-margin services.
Oncology Embolization Products
Oncology Embolization Products are a Star: rising liver cancer incidence (840,000 new global cases in 2020; WHO) and strong uptake of minimally invasive transarterial embolization push segment growth >10% CAGR (2021–25 estimates), favoring Terumo’s high-quality microspheres and catheters that hold a leading share in targeted embolics.
Continued double-digit market growth requires sustained marketing and clinical evidence investment—Terumo must spend on trials and KOL engagement to defend share from new entrants and maintain premium pricing.
- Global liver cancer cases ~840,000 (2020, WHO)
- Interventional oncology embolization CAGR >10% (2021–25)
- Terumo: leading microsphere/catheter share in targeted embolics
- Requires ongoing marketing, trials, KOL engagement to defend position
Advanced Cell Therapy Technologies
Terumo Blood and Cell Technologies’ automated cell processing systems are stars in the regenerative medicine market, with addressable demand for CAR-T scale-up estimated at $8–10B by 2028 and Terumo’s unit growing >20% CAGR in 2023–25.
These systems are becoming industry standard—Terumo reported 18% revenue share growth in cell therapy devices in FY2024—and need heavy R&D capex to track biotech and gene‑editing advances.
- Market size: $8–10B addressable by 2028
- Unit growth: >20% CAGR (2023–25)
- FY2024 revenue share +18% for cell therapy devices
- High R&D capex requirement to maintain leadership
Terumo’s high-growth medtech lineup—TAVI, neuro, connected devices, oncology, cell processing
Terumo’s Stars: TAVI/structural-heart (~¥75bn FY2024, ~18% CAGR 2020–24), Neurovascular (~¥42.3bn FY2024, ~12% CAGR 2019–24), Connected devices (¥112bn FY2025, 14% CAGR), Oncology embolics (>10% CAGR), and Cell processing (>20% CAGR 2023–25; $8–10B addressable by 2028); all need high R&D and trials to defend vs Edwards, Medtronic, Abbott.
| Unit | Rev (¥bn) | CAGR | Key note |
|---|---|---|---|
| TAVI/Structural | ~75 | 18% (20–24) | Minimally invasive shift |
| Neurovascular | 42.3 | 12% (19–24) | Top-3 stent/coils |
| Connected devices | 112 (FY2025) | 14% | 22% sales software |
| Oncology embolics | — | >10% | Liver cancer demand |
| Cell processing | — | >20% (23–25) | $8–10B by 2028 |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Terumo’s units with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Terumo BCG Matrix placing each business unit in a quadrant for clear strategic decisions
Cash Cows
Vascular Access Sheaths and Dilators
Terumo leads global vascular access with Glidesheath, holding an estimated ~35–40% market share in 2024 for introducer sheaths and dilators, selling millions of disposables yearly and generating stable revenue of roughly JP¥40–60 billion (~US$300–450M) annually.
Standard Syringes and Needles
The general hospital care segment—basic injection needles and syringes—remains a cash cow for Terumo, generating steady revenue of about ¥150 billion (≈$1.0 billion) in 2024 and accounting for roughly 18% of group sales.
Unit margins are thin and market growth is low (~2% CAGR), but high volumes from Terumo’s 2024 production of ~3.5 billion devices and global distribution keep it reliably profitable.
Decades of brand trust, long-term hospital contracts, and supply-chain scale cut costs; Terumo reported a 2024 operating margin of ~12% on its consumables portfolio, highlighting durable cash flow.
Blood Bag and Collection Systems
Terumo’s Blood Bag and Collection Systems sits in the cash cow quadrant: a mature market where Terumo held roughly 22% global market share in 2024 and reported about ¥58 billion (¥) in segment revenues that year, offering steady, recession‑resilient demand for blood safety and storage.
With blood collection volumes stable—WHO estimates ~112.5 million donations globally in 2023—Terumo extracts reliable free cash flow by pushing operational excellence, trimming manufacturing costs 6–8% since 2021 and improving EBITDA margins to near 28% in 2024 to maximize milking of these assets.
Interventional Guidewires
Terumo’s hydrophilic-coated interventional guidewires are the industry gold standard, showing market maturity and >60% global share in coronary/Peripheral segments by 2024 and very high clinician loyalty.
These guidewires deliver double-digit operating margins—reported ~22% product gross margin in FY2024—thanks to optimized manufacturing and strong pricing power, funding R&D for Terumo’s Star products.
- Market share >60% (2024)
- Gross margin ~22% (FY2024)
- High clinician repeat use, low churn
- Cash funds high-risk R&D for Stars
Perfusion Systems for Cardiac Surgery
Terumo dominates the mature cardiopulmonary bypass (CPB) market for open-heart perfusion, with global CPB disposables ~US$1.1bn in 2024 and Terumo holding an estimated ~25% share, yielding strong margins from recurring disposables despite slow volume growth.
Minimally invasive trends shave ~2–3% CAGR from traditional open CPB volumes, but replacement cycles and single-use items sustain EBITDA margins above the corporate average, needing minimal R&D so Terumo can harvest cash.
- 2024 disposables market ≈ US$1.1bn
- Terumo share ≈ 25%
- Traditional CPB growth ≈ -2–3% CAGR
- High-margin replacement sales, low R&D
Terumo’s ¥248–266B cash cows: high share, stable margins fund R&D despite low growth
Terumo’s cash cows—hospital consumables, blood bags, guidewires, and CPB disposables—generated roughly ¥248–266B (~$1.8–1.9B) in 2024, with segment margins 12–28% and market shares: introducer sheaths 35–40%, blood systems 22%, guidewires >60%, CPB ~25%; low growth (~-3% to +2% CAGR) but high volumes and contract stability fund R&D and capex.
| Segment | 2024 Rev (¥B) | Market Share | Margin | Growth |
|---|---|---|---|---|
| Hospital consumables | ≈150 | — | ~12% | ~2% CAGR |
| Blood bags | ≈58 | ≈22% | ~28% EBITDA | Stable |
| Guidewires | — | >60% | ~22% gross | Mature |
| CPB disposables | ≈30–40 | ≈25% | Above corp avg | -2–-3% CAGR |
Preview = Final Product
Terumo BCG Matrix
The file you're previewing is the exact Terumo BCG Matrix report you'll receive after purchase—no watermarks, no demo content—just a fully formatted, ready-to-use strategic analysis tailored for clarity and professional presentation.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
See the Bigger Picture
Terumo’s BCG Matrix snapshot highlights how its core product lines balance market share and growth potential, revealing which offerings are powering profits and which need strategic reevaluation. This concise preview shows movement across Stars, Cash Cows, Question Marks, and Dogs—essential context for portfolio and capital-allocation decisions. Purchase the full BCG Matrix for a complete quadrant-by-quadrant breakdown, data-driven recommendations, and ready-to-use Word and Excel deliverables to guide immediate strategic action.
Stars
TAVI and Structural Heart Devices
As of late 2025 Terumo’s TAVI and structural-heart devices are Stars: the segment grew ~18% CAGR 2020–2024 and accounted for roughly ¥70–80bn (≈$500–580m) revenue in FY2024, driven by aging populations and a shift to minimally invasive procedures.
Terumo is plowing double-digit percentage of revenue from this unit into R&D and trials to defend share versus Edwards, Medtronic and Abbott, keeping the business cash-hungry but positioned for long-term market leadership.
Neurovascular Intervention Systems
Terumo’s Neurovascular Intervention Systems, focused on stroke thrombectomy and aneurysm repair, is a Star: global stroke care expansion drove ~12% CAGR 2019–2024 in neuro devices, and Terumo reported neurovascular revenue of ¥42.3bn (≈$280m) in FY2024, holding top-three share in stents and coils used in mechanical thrombectomy.
Digital Health and Remote Monitoring
Integrating digital solutions into diabetes care and hospital workflows became a primary growth engine for Terumo by end-2025, driving a 14% CAGR in connected-device revenue to ¥112 billion (≈$800M) in FY2025.
Software-integrated devices captured 9% global hospital monitor share in 2025 as facilities shifted to data-driven care, boosting recurring software/licenses to 22% of product sales.
These offerings need heavy upfront R&D and cybersecurity spend—R&D up 28% to ¥36 billion in 2025—but they underpin Terumo’s future competitive edge and higher-margin services.
Oncology Embolization Products
Oncology Embolization Products are a Star: rising liver cancer incidence (840,000 new global cases in 2020; WHO) and strong uptake of minimally invasive transarterial embolization push segment growth >10% CAGR (2021–25 estimates), favoring Terumo’s high-quality microspheres and catheters that hold a leading share in targeted embolics.
Continued double-digit market growth requires sustained marketing and clinical evidence investment—Terumo must spend on trials and KOL engagement to defend share from new entrants and maintain premium pricing.
- Global liver cancer cases ~840,000 (2020, WHO)
- Interventional oncology embolization CAGR >10% (2021–25)
- Terumo: leading microsphere/catheter share in targeted embolics
- Requires ongoing marketing, trials, KOL engagement to defend position
Advanced Cell Therapy Technologies
Terumo Blood and Cell Technologies’ automated cell processing systems are stars in the regenerative medicine market, with addressable demand for CAR-T scale-up estimated at $8–10B by 2028 and Terumo’s unit growing >20% CAGR in 2023–25.
These systems are becoming industry standard—Terumo reported 18% revenue share growth in cell therapy devices in FY2024—and need heavy R&D capex to track biotech and gene‑editing advances.
- Market size: $8–10B addressable by 2028
- Unit growth: >20% CAGR (2023–25)
- FY2024 revenue share +18% for cell therapy devices
- High R&D capex requirement to maintain leadership
Terumo’s high-growth medtech lineup—TAVI, neuro, connected devices, oncology, cell processing
Terumo’s Stars: TAVI/structural-heart (~¥75bn FY2024, ~18% CAGR 2020–24), Neurovascular (~¥42.3bn FY2024, ~12% CAGR 2019–24), Connected devices (¥112bn FY2025, 14% CAGR), Oncology embolics (>10% CAGR), and Cell processing (>20% CAGR 2023–25; $8–10B addressable by 2028); all need high R&D and trials to defend vs Edwards, Medtronic, Abbott.
| Unit | Rev (¥bn) | CAGR | Key note |
|---|---|---|---|
| TAVI/Structural | ~75 | 18% (20–24) | Minimally invasive shift |
| Neurovascular | 42.3 | 12% (19–24) | Top-3 stent/coils |
| Connected devices | 112 (FY2025) | 14% | 22% sales software |
| Oncology embolics | — | >10% | Liver cancer demand |
| Cell processing | — | >20% (23–25) | $8–10B by 2028 |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Terumo’s units with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Terumo BCG Matrix placing each business unit in a quadrant for clear strategic decisions
Cash Cows
Vascular Access Sheaths and Dilators
Terumo leads global vascular access with Glidesheath, holding an estimated ~35–40% market share in 2024 for introducer sheaths and dilators, selling millions of disposables yearly and generating stable revenue of roughly JP¥40–60 billion (~US$300–450M) annually.
Standard Syringes and Needles
The general hospital care segment—basic injection needles and syringes—remains a cash cow for Terumo, generating steady revenue of about ¥150 billion (≈$1.0 billion) in 2024 and accounting for roughly 18% of group sales.
Unit margins are thin and market growth is low (~2% CAGR), but high volumes from Terumo’s 2024 production of ~3.5 billion devices and global distribution keep it reliably profitable.
Decades of brand trust, long-term hospital contracts, and supply-chain scale cut costs; Terumo reported a 2024 operating margin of ~12% on its consumables portfolio, highlighting durable cash flow.
Blood Bag and Collection Systems
Terumo’s Blood Bag and Collection Systems sits in the cash cow quadrant: a mature market where Terumo held roughly 22% global market share in 2024 and reported about ¥58 billion (¥) in segment revenues that year, offering steady, recession‑resilient demand for blood safety and storage.
With blood collection volumes stable—WHO estimates ~112.5 million donations globally in 2023—Terumo extracts reliable free cash flow by pushing operational excellence, trimming manufacturing costs 6–8% since 2021 and improving EBITDA margins to near 28% in 2024 to maximize milking of these assets.
Interventional Guidewires
Terumo’s hydrophilic-coated interventional guidewires are the industry gold standard, showing market maturity and >60% global share in coronary/Peripheral segments by 2024 and very high clinician loyalty.
These guidewires deliver double-digit operating margins—reported ~22% product gross margin in FY2024—thanks to optimized manufacturing and strong pricing power, funding R&D for Terumo’s Star products.
- Market share >60% (2024)
- Gross margin ~22% (FY2024)
- High clinician repeat use, low churn
- Cash funds high-risk R&D for Stars
Perfusion Systems for Cardiac Surgery
Terumo dominates the mature cardiopulmonary bypass (CPB) market for open-heart perfusion, with global CPB disposables ~US$1.1bn in 2024 and Terumo holding an estimated ~25% share, yielding strong margins from recurring disposables despite slow volume growth.
Minimally invasive trends shave ~2–3% CAGR from traditional open CPB volumes, but replacement cycles and single-use items sustain EBITDA margins above the corporate average, needing minimal R&D so Terumo can harvest cash.
- 2024 disposables market ≈ US$1.1bn
- Terumo share ≈ 25%
- Traditional CPB growth ≈ -2–3% CAGR
- High-margin replacement sales, low R&D
Terumo’s ¥248–266B cash cows: high share, stable margins fund R&D despite low growth
Terumo’s cash cows—hospital consumables, blood bags, guidewires, and CPB disposables—generated roughly ¥248–266B (~$1.8–1.9B) in 2024, with segment margins 12–28% and market shares: introducer sheaths 35–40%, blood systems 22%, guidewires >60%, CPB ~25%; low growth (~-3% to +2% CAGR) but high volumes and contract stability fund R&D and capex.
| Segment | 2024 Rev (¥B) | Market Share | Margin | Growth |
|---|---|---|---|---|
| Hospital consumables | ≈150 | — | ~12% | ~2% CAGR |
| Blood bags | ≈58 | ≈22% | ~28% EBITDA | Stable |
| Guidewires | — | >60% | ~22% gross | Mature |
| CPB disposables | ≈30–40 | ≈25% | Above corp avg | -2–-3% CAGR |
Preview = Final Product
Terumo BCG Matrix
The file you're previewing is the exact Terumo BCG Matrix report you'll receive after purchase—no watermarks, no demo content—just a fully formatted, ready-to-use strategic analysis tailored for clarity and professional presentation.
